Ablation of Cbl-b provides protection against transplanted and spontaneous tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
A significant challenge to efforts aimed at inducing effective antitumor immune responses is that CD8(+) T cells, which play a prominent role in these responses, may be unable to respond to tumors that lack costimulatory signals and that are protected by an immune suppressive environment such as that mediated by TGF-beta produced by tumor cells themselves or by infiltrating Tregs, often resulting in tolerance or anergy of tumor-specific T cells. Here we show that the in vitro activation of Cblb(-/-) CD8(+) T cells does not depend on CD28 costimulation and is resistant to TGF-beta suppression. In vivo studies further demonstrated that Cblb(-/-) mice, but not WT controls, efficiently rejected inoculated E.G7 and EL4 lymphomas that did not express B7 ligands and that introduction of the Cblb(-/-) mutation into tumor-prone ataxia telangiectasia mutated-deficient mice markedly reduced the incidence of spontaneous thymic lymphomas. Immunohistological study showed that E.G7 tumors from Cblb(-/-) mice contained massively infiltrating CD8(+) T cells. Adoptive transfer of purified Cblb(-/-) CD8(+) T cells into E.G7 tumor-bearing mice led to efficient eradication of established tumors. Thus, our data indicate that ablation of Cbl-b can be an efficient strategy for eliciting immune responses against both inoculated and spontaneous tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, CBLB has been best studied as an intracellular immune checkpoint that can be targeted in T cells to improve tumor control in mouse models (Chiang et al., 2007; Hinterleitner et al., 2012).”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Chiang et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia
Barlow, C., Hirotsune, S., Paylor, R., Liyanage, M., Eckhaus, M., Collins, F., Shiloh, Y., Crawley, J. N., Ried, T., Tagle, D., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80086-0 · Cited by 1,458
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,325
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Introduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092
The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase
Joazeiro, C. A. P., Wing, S. S., Huang, H.-K., Leverson, J. D., Hunter, T., & Liu, Y.-C. (1999) · Science · doi:10.1126/science.286.5438.309 · Cited by 1,034
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway
Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., Carbone, D. P., Paul, W. E., & Berzofsky, J. A. (2000) · Nature Immunology · doi:10.1038/82771 · Cited by 699
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
Bachmaier, K., Krawczyk, C., Kozieradzki, I., Kong, Y.-Y., Sasaki, T., Oliveira-dos-Santos, A., Mariathasan, S., Bouchard, D., Wakeham, A., Itie, A., et al. (2000) · Nature · doi:10.1038/35003228 · Cited by 666
Cbl-b regulates the CD28 dependence of T-cell activation
Chiang, Y. J., Kole, H. K., Brown, K., Naramura, M., Fukuhara, S., Hu, R.-J., Jang, I. K., Gutkind, J. S., Shevach, E., & Gu, H. (2000) · Nature · doi:10.1038/35003235 · Cited by 621
Self-citationTumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.
Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellström, I., & Hellström, K. E. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.523 · Cited by 462
c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation
Naramura, M., Jang, I.-K., Kole, H., Huang, F., Haines, D., & Gu, H. (2002) · Nature Immunology · doi:10.1038/ni855 · Cited by 390
Self-citationEssential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction
Jeon, M.-S., Atfield, A., Venuprasad, K., Krawczyk, C., Sarao, R., Elly, C., Yang, C., Arya, S., Bachmaier, K., Su, L., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.013 · Cited by 348 · cited 1×
“T cells may escape an anergic fate under conditions that normally induce immune tolerance in vivo (30).”
Strategies for designing and optimizing new generation vaccines
Berzofsky, J. A., Ahlers, J. D., & Belyakov, I. M. (2001) · Nature Reviews Immunology · doi:10.1038/35105075 · Cited by 334
Regulation of immunity by self-reactive T cells
Kronenberg, M., & Rudensky, A. (2005) · Nature · doi:10.1038/nature03725 · Cited by 309
Studies in Antibody Response of Mice to Tumour Inoculation
Gorer, P. A. (1950) · British Journal of Cancer · doi:10.1038/bjc.1950.36 · Cited by 295
Ubiquitin Ligases and the Immune Response
Liu, Y.-C. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104813 · Cited by 282
Somasundaram, R., Jacob, L., Swoboda, R., Caputo, L., Song, H., Basak, S. K., Monos, D. S., Peritt, D., Marincola, F. M., Cai, D., et al. (2002) · PubMed · Cited by 203
Immunity against cancer: lessons learned from melanoma
Houghton, A. N., Gold, J. S., & Blachere, N. E. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00195-3 · Cited by 190
Ramarathinam, L., Castle, M., Wu, Y., & Liu, Y. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1205 · Cited by 161
Enhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation
Wallin, J. J., Liang, L., Bakardjiev, A., & Sha, W. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.132 · Cited by 155
Wohlfert, E. A., Gorelik, L., Mittler, R., Flavell, R. A., & Clark, R. B. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1316 · Cited by 137
The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction
Lupher, M., Rao, N. L., Eck, M. J., & Band, H. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01484-x · Cited by 135
Liu, X., Bai, X.-F., Wen, J., Gao, J.-X., Liu, J., Lu, P., Wang, Y., Zheng, P., & Liu, Y. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1339 · Cited by 119
Restifo, N. P., Esquivel-Guadarrama, F. R., Asher, A. L., Stötter, H., Barth, R. J., Bennink, J. R., Mulé, J. J., Yewdell, J. W., & Rosenberg, S. A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1453 · Cited by 113
Helmich, B. K., & Dutton, R. W. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6500 · Cited by 88
A new era of cancer immunotherapy: converting theory to performance
Rosenberg, S. A. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.2.70 · Cited by 55
The role of B7-CD28 co-stimulation in tumor rejection
Yu, X. (1998) · International Immunology · doi:10.1093/intimm/10.6.791 · Cited by 27
Research works printed but not linked: 1
- Somasundaram, 2002, Cancer Res., 62, 5267
Cited by
Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Lipkowitz, S., & Weissman, A. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3120 · Cited by 415
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Gumber, D., & Wang, L. D. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 396
Pellegrini, M., Calzascia, T., Elford, A. R., Shahinian, A., Lin, A. E., Dissanayake, D., Dhanji, S., Nguyen, L. T., Gronski, M. A., Morre, M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1953 · Cited by 228
Metadata
- Authors
- Chiang, J. Y., Jang, I. K., Hodes, R., & Gu, H.
- Affiliations
- National Institutes of Health (US)
- Columbia University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2007-04-02
- Volume
- 117
- Issue
- 4
- Pages
- 1029-1036
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1810570
- OpenAlex
- W1855158451
- Cited by
- 124
- References
- 32
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 2 · 2014: 6 · 2013: 8 · 2012: 7
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of Immunology
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- Cbl-b, CD8+ T cells, antitumor immunity, CD28 costimulation, TGF-beta, regulatory T cells, tumor rejection, EL4 lymphoma, ATM kinase, adoptive T cell therapy, tumor immunosuppression, B7 ligands
- MeSH terms
- Animals, Lymphoma, Mice, Inbred C57BL, Neoplasm Transplantation, CD4-Positive T-Lymphocytes, Mice, Knockout, CD8-Positive T-Lymphocytes, Adaptor Proteins, Signal Transducing, Proto-Oncogene Proteins c-cbl, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.